Antihypertensive Drug Guanabenz Is Active In Vivo against both Yeast and Mammalian Prions
Open Access
- 23 April 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (4) , e1981
Abstract
Prion-based diseases are incurable transmissible neurodegenerative disorders affecting animals and humans. Here we report the discovery of the in vivo antiprion activity of Guanabenz (GA), an agonist of α2-adrenergic receptors routinely used in human medicine as an antihypertensive drug. We isolated GA in a screen for drugs active in vivo against two different yeast prions using a previously described yeast-based two steps assay. GA was then shown to promote ovine PrPSc clearance in a cell-based assay. These effects are very specific as evidenced by the lack of activity of some GA analogues that we generated. GA antiprion activity does not involve its agonist activity on α2-adrenergic receptors as other chemically close anti-hypertensive agents possessing related mechanism of action were found inactive against prions. Finally, GA showed activity in a transgenic mouse-based in vivo assay for ovine prion propagation, prolonging slightly but significantly the survival of treated animals. GA thus adds to the short list of compounds active in vivo in animal models for the treatment of prion-based diseases. Because it has been administrated for many years to treat hypertension on a daily basis, without major side-effects, our results suggest that it could be evaluated in human as a potential treatment for prion-based diseases.Keywords
This publication has 43 references indexed in Scilit:
- Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal CulturesJournal of Virology, 2007
- Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion ToxicityJournal of Neuroscience, 2007
- Peptide Aptamers Expressed in the Secretory Pathway Interfere with Cellular PrPSc FormationJournal of Molecular Biology, 2007
- Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected MiceNeuron, 2007
- A systematic review of prion therapeutics in experimental modelsBrain, 2006
- Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent TargetsJournal of Virology, 2005
- Humanized Knock-In Mice Expressing Chimeric Prion Protein Showed Varied Susceptibility to Different Human PrionsThe American Journal of Pathology, 2003
- Markedly Increased Susceptibility to Natural Sheep Scrapie of Transgenic Mice Expressing Ovine PrPJournal of Virology, 2001
- Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in SpleenJournal of General Virology, 1984
- Guanabenz A Review of its Pharmacodynamic Properties and Therapeutic Efficacy in HypertensionDrugs, 1983